Compare CROX & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CROX | LNTH |
|---|---|---|
| Founded | 1999 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.4B |
| IPO Year | 2006 | 2015 |
| Metric | CROX | LNTH |
|---|---|---|
| Price | $85.84 | $64.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 6 |
| Target Price | ★ $91.60 | $78.00 |
| AVG Volume (30 Days) | ★ 996.1K | 728.8K |
| Earning Date | 02-12-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.26 | 2.39 |
| Revenue | ★ $4,072,780,000.00 | $1,525,933,000.00 |
| Revenue This Year | N/A | $0.01 |
| Revenue Next Year | N/A | $0.26 |
| P/E Ratio | ★ $25.91 | $27.10 |
| Revenue Growth | 0.01 | ★ 1.95 |
| 52 Week Low | $73.21 | $47.25 |
| 52 Week High | $122.84 | $111.29 |
| Indicator | CROX | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 49.88 | 43.81 |
| Support Level | $83.52 | $64.25 |
| Resistance Level | $88.50 | $68.70 |
| Average True Range (ATR) | 2.65 | 2.15 |
| MACD | 0.18 | -0.39 |
| Stochastic Oscillator | 56.93 | 26.76 |
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company are the United States and other Countries.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.